[go: up one dir, main page]

DE69924135D1 - Heterozyklische kalium-kanal inhibitoren - Google Patents

Heterozyklische kalium-kanal inhibitoren

Info

Publication number
DE69924135D1
DE69924135D1 DE69924135T DE69924135T DE69924135D1 DE 69924135 D1 DE69924135 D1 DE 69924135D1 DE 69924135 T DE69924135 T DE 69924135T DE 69924135 T DE69924135 T DE 69924135T DE 69924135 D1 DE69924135 D1 DE 69924135D1
Authority
DE
Germany
Prior art keywords
heterocyclic
channel inhibitors
kalium
kalium channel
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69924135T
Other languages
English (en)
Other versions
DE69924135T2 (de
Inventor
Jianming Bao
Frank Kayser
Andrew Kotliar
H Parsons
M Rupprecht
F Claiborne
Nigel Liverton
A Claremon
J Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE69924135D1 publication Critical patent/DE69924135D1/de
Application granted granted Critical
Publication of DE69924135T2 publication Critical patent/DE69924135T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69924135T 1998-10-30 1999-10-26 Heterozyklische Kalium-Kanalinhibitoren Expired - Lifetime DE69924135T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10629298P 1998-10-30 1998-10-30
US106292P 1998-10-30
PCT/US1999/025066 WO2000025786A1 (en) 1998-10-30 1999-10-26 Heterocyclic potassium channel inhibitors

Publications (2)

Publication Number Publication Date
DE69924135D1 true DE69924135D1 (de) 2005-04-14
DE69924135T2 DE69924135T2 (de) 2006-02-23

Family

ID=22310627

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69924135T Expired - Lifetime DE69924135T2 (de) 1998-10-30 1999-10-26 Heterozyklische Kalium-Kanalinhibitoren

Country Status (8)

Country Link
US (1) US6303637B1 (de)
EP (1) EP1126849B1 (de)
JP (1) JP4764550B2 (de)
AT (1) ATE290382T1 (de)
AU (1) AU764515B2 (de)
CA (1) CA2348735C (de)
DE (1) DE69924135T2 (de)
WO (1) WO2000025786A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19923086A1 (de) * 1999-05-20 2000-11-23 Aventis Pharma Gmbh Cinnamoylaminoalkyl-substituierte Benzolsulfonamidderivate, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US7217716B2 (en) 2001-02-23 2007-05-15 Merck & Co., Inc. N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
CA2441235C (en) 2001-03-21 2011-05-24 Pharmacopeia, Inc. Aryl and biaryl compounds having mch modulatory activity
AU2002338334B8 (en) * 2001-04-03 2008-09-18 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B antagonists
CA2443672C (en) 2001-04-12 2011-03-29 Pharmacopeia, Inc. Aryl and biaryl piperidines used as mch antagonists
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
TW200307539A (en) * 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
ES2321092T3 (es) * 2002-08-29 2009-06-02 Astrazeneca Ab Derivados naftamida y sus usos.
UA83202C2 (ru) * 2002-11-26 2008-06-25 Пфайзер Продактс Инк. Фенилзамещенные пиперидины для использования в качестве активаторов рапп
CN102144961A (zh) 2003-09-18 2011-08-10 参天制药株式会社 经巩膜递送
WO2005046601A2 (en) * 2003-11-12 2005-05-26 Merck & Co., Inc. 4-phenyl piperdine sulfonyl glycine transporter inhibitors
AU2005228133B2 (en) * 2004-03-24 2011-09-08 Merck Sharp & Dohme Corp. Heteroaryl piperidine glycine transporter inhibitors
EP1768662A2 (de) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immunstimulatoren kleiner moleküle und assays für deren nachweis
DE602005024838D1 (en) * 2004-09-30 2010-12-30 Merck Sharp & Dohme Cyclopropylpiperidinglycin-transporter-inhibitor
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
CA2597590A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
EP1922311A2 (de) * 2005-09-09 2008-05-21 Brystol-Myers Squibb Company Azyklische ikur-hemmer
US7834031B2 (en) * 2005-09-29 2010-11-16 Merck Sharp & Dohme Corp. Radiolabeled glycine transporter inhibitors
JP5175736B2 (ja) * 2005-10-28 2013-04-03 メルク・シャープ・エンド・ドーム・コーポレイション ピペリジングリシン輸送体阻害剤
US8067607B2 (en) * 2006-02-01 2011-11-29 Merck Sharp & Dohme Corp. Potassium channel inhibitors
BRPI0707612B8 (pt) 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
WO2007112052A2 (en) 2006-03-23 2007-10-04 Macusight, Inc. Formulations and methods for vascular permeability-related diseases or conditions
AR074558A1 (es) * 2008-12-12 2011-01-26 Solvay Pharm Bv Espiro azepan oxazolidinonas como bloqueadores del canal de potasio kv1.3
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
EP2845851A1 (de) * 2012-05-01 2015-03-11 Sumitomo Chemical Company Limited Piperidinverbindung und verwendung davon zur schädlingsbekämpfung
TWI598325B (zh) * 2012-10-12 2017-09-11 Ｈ 朗德貝克公司 苯甲醯胺類
TW201427947A (zh) 2012-10-12 2014-07-16 Lundbeck & Co As H 環狀胺
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278541A (en) * 1966-10-11 Di-substituted-n-alkyl piperidines
BE640941A (de) *
BE636238A (de) * 1962-08-20
FR1381445A (fr) * 1963-10-23 1964-12-14 Hoechst Ag Composés de pipéridine et leur préparation
GB8707123D0 (en) 1987-03-25 1987-04-29 Pfizer Ltd Antiarrhythmic agents
IL88314A (en) 1987-11-18 1994-05-30 Tanabe Seiyaku Co History of sulfonylamino indane, their preparation and pharmaceutical preparations containing them
US5397702A (en) * 1989-03-06 1995-03-14 The Regents Of The University Of California Assay for and treatment of autoimmune diseases
IE903957A1 (en) 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
ATE167473T1 (de) 1990-08-20 1998-07-15 Eisai Co Ltd Sulfonamid-derivate
JPH08504435A (ja) * 1992-12-14 1996-05-14 メルク シヤープ エンド ドーム リミテツド タキキニン受容体拮抗剤としての４−アミノメチル／チオメチル／スルホニルメチル−４−フェニルピペリジン
US5494895A (en) * 1993-07-22 1996-02-27 Merck & Co., Inc. Scorpion peptide margatoxin with immunosuppressant activity
US5728835A (en) 1993-12-27 1998-03-17 Toa Eiyo, Ltd. Substituted cyclic amine compound, production process thereof and pharmaceutical composition for circulatory organ use containing the same
US5703093A (en) * 1995-05-31 1997-12-30 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
ZA96211B (en) 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
TW467902B (en) 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1

Also Published As

Publication number Publication date
CA2348735C (en) 2007-12-11
US6303637B1 (en) 2001-10-16
CA2348735A1 (en) 2000-05-11
EP1126849B1 (de) 2005-03-09
EP1126849A1 (de) 2001-08-29
EP1126849A4 (de) 2003-06-04
AU764515B2 (en) 2003-08-21
ATE290382T1 (de) 2005-03-15
JP2002528503A (ja) 2002-09-03
JP4764550B2 (ja) 2011-09-07
WO2000025786A1 (en) 2000-05-11
AU1133800A (en) 2000-05-22
DE69924135T2 (de) 2006-02-23

Similar Documents

Publication Publication Date Title
DE69924135D1 (de) Heterozyklische kalium-kanal inhibitoren
ATE423557T1 (de) Carbocyclische kaliumkanalhemmer
ID25853A (id) Penghambat saluran kalium
BG106585A (en) Kinase inhibitors as therapeutic agents
ATE318267T1 (de) Einige alkylendiamin-substituierte heterocyclen
NO990708L (no) Bisykliske pyrimidinderivater og deres anvendelse som antikoagulanter
PT934310E (pt) N-heterociclicos monociclicos substituidos por tioacido uteis como anti-coagulantes
ATE250571T1 (de) Kaliumkanal-blocker
NO20003233D0 (no) 4-hydrokykinolin-3-karboksamider og hydraziner som antivirale midler
ES2186874T3 (es) Analogos de m-amidinofenilo como inhibidores del factor xa.
PT813525E (pt) Derivados de benzamidina e sua utilizacao como anticoagulantes
EA199900591A1 (ru) АЗОТСОДЕРЖАЩИЕ ГЕТЕРОАРОМАТИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха
DK1131315T3 (da) Polyhydroxylerede heterocykliske derivater som antikoagulanter
BR0313330A (pt) Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4
NZ509207A (en) Thiobenzimidazole derivative compounds, and usage as chymase activity inhibitors
DE69928655D1 (de) Substituierte porphyrine
DE69935153D1 (de) Benzamide als kaliumkanal-inhibitoren
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
ATE476419T1 (de) Isochinolinon-kaliumkanalinhibitoren
EA200000204A1 (ru) Производные пирролопирролона в качестве ингибиторов эластазы нейтрофилов
SE9801494D0 (sv) Novel use
EA200100517A1 (ru) Антагонисты 5ht1 для антидепрессантной терапии
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
EA200200948A1 (ru) Лечение псориаза
TR200003203T2 (tr) Karboksaldehitin saflaştırılması

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY, N.J., US

R081 Change of applicant/patentee

Ref document number: 1126849

Country of ref document: EP

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., 07065-0900 RAHWAY, US

Effective date: 20121213

R082 Change of representative

Ref document number: 1126849

Country of ref document: EP

Representative=s name: ABITZ & PARTNER, DE

Effective date: 20121213